Transfusion Strategies for Acute Upper Gastrointestinal Bleeding

Transfusion Strategies for Acute Upper Gastrointestinal Bleeding

As compared with a liberal transfusion strategy, a restrictive strategy significantly improved outcomes in patients with acute upper gastrointestinal bleeding. We enrolled 921 patients with severe acute upper gastrointestinal... read more

High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure

High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure

The use of high-flow nasal oxygen upon ICU admission in adult patients with COVID-19 related acute hypoxemic respiratory failure may lead to an increase in ventilator-free days and a reduction in ICU length of stay, when... read more

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of SSc-PAH

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of SSc-PAH

B cell depletion therapy is a potentially effective and safe adjuvant treatment for systemic sclerosis-pulmonary arterial hypertension (SSc-PAH). Future studies in these patients can confirm whether the identified biomarkers... read more

Chloroquine/Hydroxychloroquine for Treating or Preventing COVID-19 Infection

Chloroquine/Hydroxychloroquine for Treating or Preventing COVID-19 Infection

When given along with azithromycin, hydroxychloroquine increased the risk of any unwanted effects, but made no difference to the risk of serious unwanted effects (1 study; 444 people). Compared with lopinavir plus ritonavir,... read more

Efficacy of Serum Angiotensin II Levels in Prognosis of Patients with COVID-19

Efficacy of Serum Angiotensin II Levels in Prognosis of Patients with COVID-19

The serum angiotensin II levels decrease significantly in patients with coronavirus disease 2019, and this decrease is correlated with lung damage. There was no statistical significance between the serum angiotensin II... read more

Antiviral Drugs in Hospitalised COVID-19 Patients

Antiviral Drugs in Hospitalised COVID-19 Patients

These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital... read more

Single Troponin Testing in ED Patients With Suspected Acute Myocardial Infarction

Single Troponin Testing in ED Patients With Suspected Acute Myocardial Infarction

One of the most common reasons for Emergency Department (ED) visits is chest pain. While most of these presentations are at a low risk for cardiac events, it is generally required to perform a full work-up to rule out an... read more

Functional outcome after inpatient rehabilitation in post-intensive care unit COVID-19 patients

Functional outcome after inpatient rehabilitation in post-intensive care unit COVID-19 patients

These findings suggest that post-acute COVID-19 patients might beneficiate of a motor and respiratory rehabilitation treatment. However, further studies are advised to better understand long-term sequelae of the disease. Medical... read more

Point-of-Care Ultrasound (POCUS) and COVID-19

Point-of-Care Ultrasound (POCUS) and COVID-19

COVID-19 is a disease caused by infection with SARS-CoV-2, a virus that affects multiple organ systems with numerous disease manifestations. COVID-19 has a specific tropism for the lower respiratory tract, and the most common... read more

Delirium (PRE-DELIRIC) Prediction Model for ICU Patients

Delirium (PRE-DELIRIC) Prediction Model for ICU Patients

The recalibrated PRE-DELIRIC model (version 2) for intensive care patients consists of 10 risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows... read more

Pediatric Extracorporeal Cardiopulmonary Resuscitation ELSO Guidelines

Pediatric Extracorporeal Cardiopulmonary Resuscitation ELSO Guidelines

Survival rates with good neurologic outcomes following conventional cardiopulmonary resuscitation (CPR) for cardiopulmonary arrest, either in the in-hospital (IH) or out-of-hospital settings, have improved but remain poor... read more

Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension

Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension

By overexpressing NUDT1, PAH-PASMCs hijack persistent oxidative stress in preventing incorporation of oxidized nucleotides into DNA, thus allowing the cell to escape apoptosis and proliferate. Given that NUDT1 inhibitors... read more

Key Topics in Critical Care

Key Topics in Critical Care

High quality critical care medicine is a crucial component of advanced health care. Completely revised and updated, Key Topics in Critical Care, Second Edition provides a broad knowledge base in the major areas of critical... read more

Peer support during the era of COVID-19

Peer support during the era of COVID-19

Burnout has been an issue for those in health care long before the COVID-19 pandemic, but the increased stress and anxiety we face now have caused a host of new problems. The current environment health care professionals... read more

The fragility index in randomised controlled trials of interventions for aneurysmal subarachnoid hemorrhage

The fragility index in randomised controlled trials of interventions for aneurysmal subarachnoid hemorrhage

Fragility analysis supplements the p-value and risk of bias assessment in the interpretation of results of randomised controlled trials. In this systematic review we determine the fragility index (FI) and fragility quotient... read more

No Significant Difference between Tocilizumab and Placebo in Severe COVID-19 Pneumonia Patients

No Significant Difference between Tocilizumab and Placebo in Severe COVID-19 Pneumonia Patients

In this randomized trial involving hospitalized patients with severe COVID-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. In this... read more

Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19

Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19

In critically ill patients with COVID-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. Both tocilizumab and sarilumab... read more